pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

178 catalysts · 43 phase 2 completion · 26 phase 1 completion · 22 phase 1 2 completion · 21 phase 2 initiation · 18 phase 1 initiation · 13 phase 1 2 initiation

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-07-27: 0 catalysts2026-07-28: 0 catalysts2026-07-29: 0 catalysts2026-07-30: 0 catalysts2026-07-31: 0 catalysts2026-08-01: 0 catalysts2026-08-02: 0 catalysts2026-08-03: 4 catalysts2026-08-04: 13 catalysts2026-08-05: 17 catalysts2026-08-06: 10 catalysts2026-08-07: 1 catalyst2026-08-08: 0 catalysts2026-08-09: 0 catalysts2026-08-10: 2 catalysts2026-08-11: 1 catalyst2026-08-12: 1 catalyst2026-08-13: 1 catalyst2026-08-14: 0 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 0 catalysts2026-08-18: 1 catalyst2026-08-19: 0 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 0 catalysts2026-08-27: 0 catalysts2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 0 catalysts2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 0 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 0 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 0 catalysts2026-10-14: 0 catalysts2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 0 catalysts2026-10-20: 1 catalyst2026-10-21: 1 catalyst2026-10-22: 2 catalysts2026-10-23: 0 catalysts2026-10-24: 0 catalysts2026-10-25: 0 catalysts
view
agendamonth
sort
soonestlatesttypesponsoralpha
TA: dermatology×TA: oncology×from 2017-05-02×clear all
type
  • phase 2 completion43
  • phase 1 completion26
  • phase 1 2 completion22
  • phase 2 initiation21
  • phase 1 initiation18
  • phase 1 2 initiation13
  • phase 0 trial completion7
  • phase 3 completion5
  • phase 3 initiation4
  • constraining patent expiry europe3
  • therapy area
    • Oncology148
    • Infectious Disease46
    • Cardiology37
    • Immunology35
    • Dermatology31
    • Pulmonology22
    • Women's Health19
    • Ophthalmology16
    • Pain15

    Week of Apr 27, 2026

    50
    ›Apr 27, 2026phase 2 initiation98d agoNational Cancer Institute US — cyclophosphamide (Phase II Trial Initiation)cyclophosphamide

    Therapy area: Oncology. Indication: Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)

    full page →cyclophosphamide →source: globaldata
    ›Apr 27, 2026phase 2 initiation98d agoChongqing Cancer Hospital — ondansetron (Phase II Trial Initiation)ondansetron ODT

    Therapy area: Oncology. Indication: Ovarian Cancer

    full page →ondansetron ODT →source: globaldata
    ›Apr 27, 2026phase 2 3 completion98d agoAnthem Biosciences Ltd — berubicin hydrochloride (Phase II/III Trial Completion)berubicin hydrochloride

    Therapy area: Oncology. Indication: Glioblastoma Multiforme (GBM), Recurrent Glioblastoma Multiforme (GBM)

    full page →berubicin hydrochloride →source: globaldata
    ›Apr 27, 2026phase 2 3 initiation98d agoKLES Dr Prabhakar Kore Hospital & Medical Research Centre — esmolol (Phase II/III Trial Initiation)esmolol

    Therapy area: Dermatology. Indication: Diabetic Foot Ulcers

    full page →esmolol →source: globaldata
    ›Apr 27, 2026phase 3 completion98d agoCellCarta Biosciences Inc — elranatamab (Phase III Trial Completion)elranatamab

    Therapy area: Oncology. Indication: Multiple Myeloma (Kahler Disease), Refractory Multiple Myeloma, Relapsed Multiple Myeloma

    full page →elranatamab →source: globaldata
    ›Apr 27, 2026phase 3 initiation98d agoSun Pharmaceutical Industries Ltd — ruxolitinib (Phase III Trial Initiation)ruxolitinib

    Therapy area: Dermatology. Indication: Vitiligo

    full page →ruxolitinib →source: globaldata
    ›Apr 27, 2026phase 3 initiation98d agoSiriraj Hospital — tranexamic acid (Phase III Trial Initiation)tranexamic acid

    Therapy area: Cardiovascular, Dermatology. Indication: Melasma (Chlosma), Venous Thromboembolism

    full page →tranexamic acid →source: globaldata
    ›Apr 28, 2026phase 1 completion97d agoNational Cancer Institute US — undisclosed chemotherapy (Phase I Trial Completion)undisclosed chemotherapy

    Therapy area: Gastrointestinal, Oncology. Indication: Bile Duct Cancer (Cholangiocarcinoma), Hepatocellular Carcinoma, Liver Cancer, Liver Cirrhosis, Metastatic Liver Cancer

    full page →undisclosed chemotherapy →source: globaldata
    ›Apr 28, 2026phase 1 completion97d agoBeijing Cancer Hospital — JCXH-212 (Phase I Trial Completion)JCXH-212

    Therapy area: Oncology. Indication: Non-Small Cell Lung Cancer, Solid Tumor

    full page →JCXH-212 →source: globaldata
    ›Apr 28, 2026phase 1 completion97d agoBio-Innova Co Ltd — clarithromycin (Phase I Trial Completion)clarithromycin

    Therapy area: Central Nervous System, Dermatology, Ear Nose Throat Disorders, Gastrointestinal, Genito Urinary System, Infectious Disease, Mouth and Dental Disorders, Respiratory. Indication: Abscess, Acne Vulgaris, Acute Bacterial Sinusitis, Acute Bronchitis, Acute Pharyngitis, Bacterial Pneumonia, Bacterial Respiratory Tract Infections, Bartonella Infections, Bronchitis, Carbuncle, Cellulitis, Chlamydia trachomatis Pneumonia, Chronic Bronchitis, Community Acquired Pneumonia, Community-Acquired

    full page →clarithromycin →source: globaldata
    ›Apr 28, 2026phase 1 initiation97d agoVirginia Commonwealth University — fluorouracil (Phase I Trial Initiation)Efudex

    Therapy area: Dermatology. Indication: Burns

    full page →Efudex →source: globaldata
    ›Apr 28, 2026phase 2 completion97d agoTianjin Medical University Cancer Institute and Hospital — AG [gemcitabine + nab-paclitaxel] (Phase II Trial Completion)AG [gemcitabine + nab-paclitaxel]

    Therapy area: Oncology. Indication: Pancreatic Cancer

    full page →AG [gemcitabine + nab-paclitaxel] →source: globaldata
    ›Apr 28, 2026phase 2 completion97d agoHackensack Meridian Health Inc — carboplatin (Phase II Trial Completion)Carboplatin Pfizer

    Therapy area: Oncology. Indication: Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma

    full page →Carboplatin Pfizer →source: globaldata
    ›Apr 28, 2026phase 2 completion97d agoShanghai Pulmonary Hospital — undisclosed programmed cell death protein 1 inhibitor (Phase II Trial Completion)undisclosed programmed cell death protein 1 inhibitor

    Therapy area: Oncology. Indication: Non-Small Cell Lung Cancer

    full page →undisclosed programmed cell death protein 1 inhibitor →source: globaldata
    ›Apr 28, 2026phase 2 initiation97d agoFudan University Shanghai Cancer Center — YZJ-2440 (Phase II Trial Initiation)YZJ-2440

    Therapy area: Oncology. Indication: Breast Cancer, Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer), Solid Tumor

    full page →YZJ-2440 →source: globaldata
    ›Apr 28, 2026phase 2 initiation97d agoAP Biosciences Inc — B-1962 (Phase II Trial Initiation)B-1962

    Therapy area: Oncology. Indication: Solid Tumor

    full page →B-1962 →source: globaldata
    ›Apr 28, 2026phase 2 initiation97d agoRise Biopharmaceutical Ltd — RP-72 (Phase II Trial Initiation)RP-72

    Therapy area: Oncology. Indication: Metastatic Pancreatic Cancer, Pancreatic Cancer

    full page →RP-72 →source: globaldata
    ›Apr 28, 2026phase 3 completion97d agoSun Yat-sen Memorial Hospital — capecitabine (Phase III Trial Completion)capecitabine

    Therapy area: Oncology. Indication: Nasopharyngeal Cancer

    full page →capecitabine →source: globaldata
    ›Apr 29, 2026phase 0 trial completion96d agoDana-Farber Cancer Institute Inc — atezolizumab (Phase 0 Trial Completion)atezolizumab

    Therapy area: Oncology. Indication: Hepatocellular Carcinoma, Liver Cancer

    full page →atezolizumab →source: globaldata
    ›Apr 29, 2026phase 1 completion96d agoBoehringer Ingelheim International GmbH — BI-765179 (Phase I Trial Completion)BI-765179

    Therapy area: Oncology. Indication: Cervical Cancer, Colorectal Cancer, Cutaneous Squamous Cell Carcinoma (cSCC), Esophageal Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Gastric Cancer, Head And Neck Cancer, Head And Neck Squamous Cell Carcinoma (HNSC), Hepatocellular Carcinoma, Hypopharyngeal Cancer, Laryngeal Cancer, Malignant Pleural Mesothelioma, Melanoma, Non-Small Cell Lung Carcinoma, Oral Cancer, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Ovarian Cancer, Pancreatic Cancer, Re

    full page →BI-765179 →source: globaldata
    ›Apr 29, 2026phase 1 initiation96d agoTerSera Therapeutics LLC — goserelin LA (Phase I Trial Initiation)goserelin LA

    Therapy area: Oncology. Indication: Breast Cancer, Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer), Metastatic Breast Cancer

    full page →goserelin LA →source: globaldata
    ›Apr 29, 2026phase 2 completion96d agoCARsgen Therapeutics Holdings Ltd — CT-0594CP CAR-T Cells (Phase II Trial Completion)CT-0594CP CAR-T Cells

    Therapy area: Oncology. Indication: Multiple Myeloma (Kahler Disease), Plasma Cell Neoplasm, Refractory Multiple Myeloma, Relapsed Multiple Myeloma

    full page →CT-0594CP CAR-T Cells →source: globaldata
    ›Apr 29, 2026phase 2 completion96d agoBangalore Medical College and Research Institute — dinoprostone (Phase II Trial Completion)dinoprostone ER

    Therapy area: Dermatology. Indication: Vitiligo

    full page →dinoprostone ER →source: globaldata
    ›Apr 29, 2026phase 2 initiation96d agoNational Cancer Institute US — (daratumumab + hyaluronidase (human recombinant)) (Phase II Trial Initiation)(daratumumab + hyaluronidase (human recombinant))

    Therapy area: Oncology. Indication: Multiple Myeloma (Kahler Disease), Refractory Multiple Myeloma

    full page →(daratumumab + hyaluronidase (human recombinant)) →source: globaldata
    ›Apr 29, 2026phase 2 initiation96d agoGoa Medical College — diclofenac (Phase II Trial Initiation)diclofenac ER

    Therapy area: Oncology, Toxicology. Indication: Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome), Colon Tumor

    full page →diclofenac ER →source: globaldata
    ›Apr 29, 2026phase 2 results96d agoSt. Vincent Health System — [177Lu]Lu-PSMA-597 (Phase II Trial Results)[177Lu]Lu-PSMA-597

    Therapy area: Oncology. Indication: Hormone-Sensitive Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Prostate Cancer, Prostate Cancer

    full page →[177Lu]Lu-PSMA-597 →source: globaldata
    ›Apr 29, 2026phase 3 completion96d agoAstraZeneca Plc — durvalumab (Phase III Trial Completion)durvalumab

    Therapy area: Genito Urinary System, Oncology. Indication: Bladder Cancer, Bladder Carcinoma, Kidney Cancer (Renal Cell Cancer), Metastatic Transitional (Urothelial) Tract Cancer, Renal Stones/Calculi, Transitional Cell Cancer (Urothelial Cell Cancer), Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Ureter Cancer, Urethral Cancer

    full page →durvalumab →source: globaldata
    ›Apr 29, 2026phase 3 initiation96d agoIncyte Corp — retifanlimab (Phase III Trial Initiation)retifanlimab

    Therapy area: Oncology. Indication: Head And Neck Cancer, Head And Neck Squamous Cell Carcinoma (HNSC), Hypopharyngeal Cancer, Laryngeal Cancer, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Recurrent Head And Neck Squamous Cell Carcinoma

    full page →retifanlimab →source: globaldata
    ›Apr 29, 2026phase 3 initiation96d agoInstitute of Hematology and Blood Diseases Hospital — venetoclax (Phase III Trial Initiation)venetoclax

    Therapy area: Oncology. Indication: Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)

    full page →venetoclax →source: globaldata
    ›Apr 29, 2026phase iv trial initiation96d agoNucleic Acids to the Rescue GmbH — undisclosed chemotherapy (Phase IV Trial Initiation)undisclosed chemotherapy

    Therapy area: Oncology. Indication: Small-Cell Lung Cancer

    full page →undisclosed chemotherapy →source: globaldata
    ›Apr 30, 2026constraining patent expiry europe95d agoCumberland Pharmaceuticals Inc — telavancin hydrochloride (Constraining Patent Expiry (Europe))telavancin hydrochloride

    Therapy area: Cardiovascular, Dermatology, Infectious Disease, Respiratory. Indication: Anthrax, Bacteremia, Bacterial Endocarditis, Bacterial Pneumonia, Complicated Skin And Skin Structure Infections (cSSSI), Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections, Hospital Acquired Pneumonia (HAP), Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, Skin And Soft Tissue Infections, Ventilator Associated Pneumonia (VAP)

    full page →telavancin hydrochloride →source: globaldata
    ›Apr 30, 2026fda advisory committee meeting95d agoAstraZeneca Plc — camizestrant (FDA Advisory Committee Meeting)camizestrant

    Therapy area: Oncology. Indication: Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)

    full page →camizestrant →source: globaldata
    ›Apr 30, 2026fda advisory committee meeting95d agoAstraZeneca Plc — capivasertib (FDA Advisory Committee Meeting)capivasertib

    Therapy area: Oncology. Indication: Hormone-Sensitive Prostate Cancer

    full page →capivasertib →source: globaldata
    ›Apr 30, 2026phase 0 trial completion95d agoRuijin Hospital — dexmedetomidine (Phase 0 Trial Completion)dexmedetomidine

    Therapy area: Central Nervous System, Dermatology. Indication: Burns, Pain, Sedation

    full page →dexmedetomidine →source: globaldata
    ›Apr 30, 2026phase 0 trial completion95d agoSecond Affiliated Hospital of Anhui Medical University — yingtao shujie paste (Phase 0 Trial Completion)yingtao shujie paste

    Therapy area: Oncology, Women's Health. Indication: Breast Cancer, Breast Hyperplasia

    full page →yingtao shujie paste →source: globaldata
    ›Apr 30, 2026phase 0 trial completion95d agoShanghai Jiao Tong University — insulin (Phase 0 Trial Completion)insulin

    Therapy area: Dermatology. Indication: Unspecified Dermatological Disorders

    full page →insulin →source: globaldata
    ›Apr 30, 2026phase 0 trial completion95d agoFoundation for the Promotion of Health and Biomedical Research of Valencia — Aquacel Ag + (Phase 0 Trial Completion)Aquacel Ag +

    Therapy area: Dermatology. Indication: Pressure Ulcers

    full page →Aquacel Ag + →source: globaldata
    ›Apr 30, 2026phase 0 trial completion95d agoJiangsu Maoxing Technology Co Ltd — MT-026 (Phase 0 Trial Completion)MT-026

    Therapy area: Oncology. Indication: Glioma

    full page →MT-026 →source: globaldata
    ›Apr 30, 2026phase 0 trial completion95d agoFirst Affiliated Hospital of Anhui Medical University — esketamine (Phase 0 Trial Completion)esketamine

    Therapy area: Central Nervous System, Oncology. Indication: Post-Operative Pain, Thyroid Cancer

    full page →esketamine →source: globaldata
    ›Apr 30, 2026phase 0 trial initiation95d agoWashington University School of Medicine — asciminib hydrochloride (Phase 0 Trial Initiation)asciminib hydrochloride

    Therapy area: Oncology. Indication: Brain Tumor

    full page →asciminib hydrochloride →source: globaldata
    ›Apr 30, 2026phase 1 completion95d agoChugai Pharmaceutical Co Ltd — tocilizumab (Phase I Trial Completion)tocilizumab

    Therapy area: Oncology. Indication: B-Cell Non-Hodgkin Lymphoma, Follicular Lymphoma

    full page →tocilizumab →source: globaldata
    ›Apr 30, 2026phase 1 completion95d agoNational Cancer Institute Center for Cancer Research — Anti-CD19/CD20/CD22 CAR T-cells (Phase I Trial Completion)Anti-CD19/CD20/CD22 CAR T-cells

    Therapy area: Oncology. Indication: Acute Lymphoblastic Lymphoma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia), B-Cell Leukemia, Chronic Lymphocytic Leukemia (CLL), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Lymphoma, Non-Hodgkin Lymphoma, Unspecified B-Cell Lymphomas

    full page →Anti-CD19/CD20/CD22 CAR T-cells →source: globaldata
    ›Apr 30, 2026phase 1 completion95d agoEOC Pharma Ltd — EOC-237 (Phase I Trial Completion)EOC-237

    Therapy area: Oncology. Indication: Solid Tumor

    full page →EOC-237 →source: globaldata
    ›Apr 30, 2026phase 1 completion95d agoChangzhou Hengbang Pharmaceutical Co Ltd — risvutatug rezetecan (Phase I Trial Completion)risvutatug rezetecan

    Therapy area: Oncology. Indication: Small-Cell Lung Cancer

    full page →risvutatug rezetecan →source: globaldata
    ›Apr 30, 2026phase 1 completion95d agoOncoNano Medicine Inc — cemiplimab (Phase I Trial Completion)cemiplimab

    Therapy area: Oncology. Indication: Basal Cell Carcinoma (Basal Cell Epithelioma), Bladder Cancer, Carcinomas, Cervical Cancer, Cutaneous Squamous Cell Carcinoma (cSCC), Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Head And Neck Squamous Cell Carcinoma (HNSC), Lymphoma, Mantle Cell Lymphoma, Melanoma, Non-Hodgkin Lymphoma, Skin Cancer, Solid Tumor, Triple-Negative Breast Cancer (TNBC), Uveal Melanoma

    full page →cemiplimab →source: globaldata
    ›Apr 30, 2026phase 1 completion95d agoNational Cancer Institute US — tuvusertib (Phase I Trial Completion)tuvusertib

    Therapy area: Oncology. Indication: Adenocarcinoma, Endometrial Cancer, Ovarian Cancer

    full page →tuvusertib →source: globaldata
    ›Apr 30, 2026phase 1 completion95d agoTakeda Pharmaceutical Co Ltd — Cabometyx (Phase I Trial Completion)cabozantinib s-malate

    Therapy area: Oncology. Indication: Solid Tumor

    full page →cabozantinib s-malate →source: globaldata
    ›Apr 30, 2026phase 1 completion95d agoCellenkos Inc — CK-0804 (Phase I Trial Completion)CK-0804

    Therapy area: Oncology. Indication: Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis), Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF)

    full page →CK-0804 →source: globaldata
    ›Apr 30, 2026phase 1 completion95d agoBeOne Medicines AG — BG-89894 (Phase I Trial Completion)BG-89894

    Therapy area: Oncology. Indication: Adenocarcinoma Of The Gastroesophageal Junction, Advanced Malignancy, Bladder Cancer, Esophageal Cancer, Gastric Cancer, Liver Cancer, Malignant Mesothelioma, Non-Small Cell Lung Cancer, Pancreatic Cancer, Solid Tumor

    full page →BG-89894 →source: globaldata
    ›Apr 30, 2026phase 1 completion95d agoAngel Pharmaceuticals Inc — soquelitinib (Phase I Trial Completion)soquelitinib

    Therapy area: Oncology. Indication: Anaplastic Large Cell Lymphoma (ALCL), Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Cutaneous T-Cell Lymphoma, Natural Killer Cell Lymphomas, Peripheral T-Cell Lymphomas (PTCL), T-Cell Leukemia, T-Cell Lymphomas

    full page →soquelitinib →source: globaldata
    ← prev
    page 2 of 4
    next →
    $AZN169.64-0.99%
    $AZN169.64-0.99%
    $CPIX6.6800-0.74%
    $INCY119.52-2.82%
    $AZN169.64-0.99%
    $TAK17.09-0.93%
    $ONC316.01-1.88%